Autorisation d’accès précoce refusée à la spécialité FASENRA (benralizumab) dans l’indication « traitement des patients adultes atteints de granulomatose éosinophilique avec polyangéite et non répondeurs à mépolizumab».
See also
HAS opinions and decisions
30/08/2024
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
0nUuePfucYYE6rKU
